Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in New Zealand

Total 5822 results

Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo (GLOW 1)

Chronic Obstructive Pulmonary Disease

Russian Federation, Singapore, United States, Canada, Korea, Republic of, Japan, Spain, Turkey, Romania, Australia, Netherlands
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

Exacerbations and Their Outcomes International (EXACOS International) (EXACOS-Intl)

Chronic Obstructive Pulmonary Disease

Taiwan, Russian Federation, Mexico, Chile
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
US Department of Veterans Affairs

Terminated

Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH)

Emphysema | COPD

United States
Novartis Pharmaceuticals

Completed

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (MOVE)

Chronic Obstructive Pulmonary Disease

Germany
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Canada, Bulgaria, Hungary, Russian Federation, Denmark, Argentina, Mexico, Poland
GlaxoSmithKline

Completed

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy (LABD)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Active, not recruiting

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE)

Chronic Obstructive Pulmonary Disease

United States, Austria, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Belgium, Vietnam, Brazil, Hungary, Philippines, China, Korea, Republic of, Argentina, Australia, Poland, Turkey, Japan, Greece, Netherlands, Czechia, Mexico, Bulgar... and more
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Muscle Weakness

United States
Laval University
Canadian Institutes of Health Research (CIHR)

Completed

The International Nocturnal Oxygen (INOX) Trial (INOX)

Chronic Obstructive Pulmonary Disease | Nocturnal Desaturation

Spain, Canada, France, Portugal
Sunovion

Completed

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Belgium, Australia, Israel, Spain, France, United Kingdom, Denmark, Argentina, Germany, New Zealand, South Africa, Korea, Republic of, Poland, Bulgaria, Canada, Chile, Czechia, Netherlands, Romania, Sweden, Mexico
Heidelberg University

Terminated

Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma

Obstructive Lung Diseases

Australia, Germany
Novartis Pharmaceuticals

Completed

A Study to Assess the Long-term Safety of QVA149 (ENLIGHTEN)

Chronic Obstructive Pulmonary Disease

Romania, Lithuania, Canada, France, Hungary, India, South Africa, Korea, Republic of, Latvia, United Kingdom
Icahn School of Medicine at Mount Sinai
International Biophysics Corporation; SPARK Healthcare

Terminated

Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

Covid19 | Chronic Obstructive Pulmonary Disease | Chronic Cough

United States
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
NYU Langone Health

Completed

The Effect of Distractive Auditory Stimuli (Music) on Dyspnea and Anxiety During Exercise in Adults With Chronic Respiratory Diseases

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom
AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, France, Greece, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Taiwan, Turkey, Ukraine, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Uptake Medical Corp

Completed

Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study

Emphysema

Australia, Ireland, Germany, Austria, New Zealand, United Kingdom
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
Lupin, Inc.

Completed

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Chronic Obstructive Pulmonary Disease

United States
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
Actelion

Terminated

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Spain, France
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
Boehringer Ingelheim

Completed

12 / 48 Week Pivotal PFT vs PBO in COPD I

Pulmonary Disease, Chronic Obstructive

United States, Australia, China, Germany, New Zealand, Taiwan
Verona Pharma plc
Iqvia Pty Ltd

Completed

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Chronic Obstructive Pulmonary Disease

Korea, Republic of, United States, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Romania, Russian Federation, Slovakia, United Kingdom
Boehringer Ingelheim

Completed

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Pulmonary Disease, Chronic Obstructive

Taiwan
AstraZeneca

Completed

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (HELIOS)

Chronic Obstructive Pulmonary Disease

France, Germany, Italy, Spain, United Kingdom, Austria, Hungary
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
Novartis Pharmaceuticals

Completed

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)

Chronic Obstructive Pulmonary Disease

United States, Spain, Switzerland, France, Italy, Germany, Turkey, Hungary, Norway, Slovakia, Poland, Russian Federation, Canada, Belgium, Austria, Colombia, Denmark, Finland, Greece, Israel, Mexico, United Kingdom
Pfizer

Completed

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Smoking Cessation

United States, France, Italy, Spain
Stony Brook University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Investigating the Impact of Mode of Administration on Item Response

Depression | Chronic Obstructive Pulmonary Disease | Rheumatoid Arthritis

United States
Boehringer Ingelheim

Completed

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Bellerophon Pulse Technologies

Completed

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States
Far Eastern Memorial Hospital

Completed

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Sarcopenia | COPD Exacerbation

Taiwan

Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations